Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.84 |
| ▸ | TK2 | O00142 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edoxudine SCHEMBL65580 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL9408693 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL1254185 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL21389875 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL12370767 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL5983087 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL5983091 | 1.00 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL11345587 | 0.95 | TK1 (0.78) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273340 | 0.92 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL5982016 | 0.92 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7458 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260060964-A1 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | ANTIVIRUS THERAPEUTICS (US) | 2026-03-05 | — | — | US | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| US-4851391-A | TOPICAL GEL | ROBUGEN GMBH PHARMAZEUTISCHE FABRIK (DE) | 1989-07-25 | — | — | US | claimed |
| EP-0294443-A1 | USE OF NUCLEOSIDES FOR THE MANUFACTURE OF MEDICAMENT FOR TREATMENT OF DISEASES CAUSED BY RETROVIRUS OR HEPATITIS B VIRUS. | MEDIVIR AB (SE) | 1988-12-14 | — | — | EP | claimed |
| EP-0277270-A2 | N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-08-10 | — | — | EP | claimed |
| WO-1988004662-A1 | USE OF NUCLEOSIDES FOR THE MANUFACTURE OF MEDICAMENT FOR TREATMENT OF DISEASES CAUSED BY RETROVIRUS OR HEPATITIS B VIRUS | Astra Läkemedel Aktiebolag (SE) | 1988-06-30 | — | — | WO | claimed |
| EP-0262344-A2 | N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-04-06 | — | — | EP | claimed |
| EP-0260428-A2 | Cationic surfactants and pharmaceutical compositions containing them | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-23 | — | — | EP | claimed |
| EP-0260429-A2 | N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-23 | — | — | EP | claimed |
| EP-0257400-A2 | Pharmaceutical compositions containing cationic surfactants | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-02 | — | — | EP | claimed |